New antibody drug targets Hard-to-Treat breast cancer

NCT ID NCT05160545

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 34 times

Summary

This early-phase study tests a new drug called GNC-035 in 36 people with advanced or metastatic breast cancer that has not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. The drug is a special antibody designed to attack cancer cells in multiple ways.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The Third Hospital of Changsha

    Changsha, Hunan, China

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

Conditions

Explore the condition pages connected to this study.